Identifying the Optimal Conditioning Intensity of Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Complete Remission

Background Allogeneic hematopoietic stem cell transplantation (HSCT) as consolidation therapy is considered a curative option for acute myeloid leukemia (AML) in complete remission (CR) to prevent relapse. Many studies have investigated the optimal conditioning intensity, comparing reduced-intensity...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-11, Vol.142 (Supplement 1), p.2150-2150
Hauptverfasser: Shimomura, Yoshimitsu, Komukai, Sho, Kitamura, Tetsuhisa, Sobue, Tomotaka, Yamasaki, Satoshi, Kondo, Tadakazu, Mizuno, Shohei, Harada, Kaito, Doki, Noriko, Tanaka, Masatsugu, Ito, Ayumu, Nishida, Tetsuya, Ohigashi, Hiroyuki, Uchida, Naoyuki, Matsuoka, Ken-ichi, Kanda, Yoshinobu, Onizuka, Makoto, Kawakita, Toshiro, Hiramoto, Nobuhiro, Sawa, Masashi, Fukushima, Kentaro, Kanda, Junya, Fukuda, Takahiro, Atsuta, Yoshiko, Yanada, Masamitsu
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Allogeneic hematopoietic stem cell transplantation (HSCT) as consolidation therapy is considered a curative option for acute myeloid leukemia (AML) in complete remission (CR) to prevent relapse. Many studies have investigated the optimal conditioning intensity, comparing reduced-intensity conditioning regimen (RIC) and myeloablative conditioning regimen (MAC) for patients with AML in CR. However, inconsistent results have been observed, possibly due to selection biases and significant heterogeneous treatment effects when focusing on average treatment effect. Some studies have attempted to assess treatment effects in specific subgroups, highlighting the heterogeneity conditioning intensity's impact. However, these analyses typically examined one factor at a time, overlooking potential multiple-factor combinations that might contribute to such heterogeneity.To address these limitations and surpass conventional comparison studies and subgroup analyses, machine-learning methods for group identification have been developed. In this study, we aimed to identify patient groups in which MAC or RIC had a superior PFS in patients with AML in CR using a machine-learning approach. Methods Our study included 3273 patients aged 40-69 years with AML in CR from the TRUMP2. These patients were divided into training (N=2020) and validation cohorts (N=1253). In the training cohort, we employed a group identification model to identify patient subsets. Preprocessing of variables was performed to ensure the ease of use in clinical practice. We modeled the magnitude of interaction between treatment and covariates without the main effect of covariates, thus leading to the construction of a scoring system that measures the individualized-treatment effect. The objective variable was set as 1-year PFS, and the interaction effects between treatment and covariates were estimated using a regression model with propensity score weight and LASSO regularization. The sum of the interaction term between treatment and covariates was defined as the “Conditioning Intensity Score”. Patients were categorized into high-score and low-score groups using a cut-off level of median in patients who received RIC. Subsequently, in the validation cohort, we estimated the average treatment effect of RIC compared to MAC for each group with hazard ratios (HR) using inverse treatment probability weight analysis. Results In the training cohort, the median age was 55 years (IQR, 48-61 years), with 1110
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-181621